Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Histone Modifications and Their Targeting in Lymphoid Malignancies

Miranda Fernández-Serrano
ORCID logo ,
René Winkler
,
Juliana Carvalho Santos
ORCID logo ,
Marguerite-Marie Le Pannérer
ORCID logo ,
Marcus Buschbeck
* ORCID logo ,
Gaël Roué
* ORCID logo
Version 1 : Received: 15 November 2021 / Approved: 17 November 2021 / Online: 17 November 2021 (23:45:00 CET)

A peer-reviewed article of this Preprint also exists.

Fernández-Serrano, M.; Winkler, R.; Santos, J.C.; Le Pannérer, M.-M.; Buschbeck, M.; Roué, G. Histone Modifications and Their Targeting in Lymphoid Malignancies. Int. J. Mol. Sci. 2022, 23, 253. Fernández-Serrano, M.; Winkler, R.; Santos, J.C.; Le Pannérer, M.-M.; Buschbeck, M.; Roué, G. Histone Modifications and Their Targeting in Lymphoid Malignancies. Int. J. Mol. Sci. 2022, 23, 253.

Abstract

In a wide range of lymphoid neoplasms, the process of malignant transformation is associated to somatic mutations in B cells that affect the epigenetic machinery. Consequential alterations in histone modifications contribute to disease-specific changes in the transcriptional program. Affected genes commonly play important roles in cell cycle regulation, apoptosis-inducing signal transduction and DNA damage response, thus facilitating the emergence of malignant traits that impair immune surveillance and favor the emergence of different B-cell lymphoma subtypes. In the last two decades, the field has made a major effort to develop therapies that target these epigenetic alterations. In this review, we discuss which epigenetic alterations occur in non-Hodgkin B-cell lymphoma. Furthermore, we aim to present in close to comprehensive manner the current state-of-the-art in the preclinical and clinical development of epigenetic drugs. We focus on therapeutic strategies interfering with histone methylation and acetylation as these are most advanced in being deployed from the bench-to-bedside and have greatest potential to improve the prognosis of lymphoma patients.

Keywords

Non-Hodgkin lymphoma; Epigenetics; DNA methylation; HAT; HDAC; EZH2; bromodomain inhibitors; Drug combination; clinical testing

Subject

Biology and Life Sciences, Biochemistry and Molecular Biology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.